Abstract 2136P
Background
Prostate cancer (PC) patients face treatment-related sequelae that affect their health and quality of life. The PCSC Program was created in 2013 and is located in the Vancouver Prostate Centre’s urology clinic. It is a clinical, educational, and research-based program that addresses challenges experienced by PC patients from the time of diagnosis onward. The program consists of 8 “modules” listed in the table.
Methods
We describe the operational details of the PCSC Program and its metrics.
Results
A Medical Director and Program Manager set the mission, oversee the day-to-day operations, and hire and manage the allied health clinicians and support staff. Office/clinic space is rotated during the week to accommodate a sexual health RN (1.4 FTE), 2 pelvic floor physiotherapists, a nurse practitioner, a registered dietitian, a clinical exercise physiologist (all 0.2 FTE), and a clinical counsellor (0.4 FTE). As of 05/2023, 3351 pts have registered for this no-cost program (Table). In 4/2020, the real-time group education sessions and clinic appointments transitioned from in-person to a hybrid with virtual options enabling the participation of patients from throughout British Columbia.
Table: 2136P
Attendance at PCSC modules for 3351 registrants from 2013 to May 2023
Modules | Attendees, n | Group education*, n (# sessions) | Clinic appointments, n (# appointments) |
Introduction to PC and primary treatment options | 945 | 955 (159) | not applicable |
Managing sexual function and intimacy | 1745 | 844 (122) | 1519 (6109) |
Management of side effects of ADT | 443 | 376 (25) | 212 (313) |
Pelvic floor physiotherapy for incontinence | 1304 | 910 (97) | 594 (2382) |
Counselling | 444 | not applicable | 444 (1629) |
Metastatic disease management | 85 | 87 (30) | not applicable |
Nutrition | 742 | 195 (31) | 361 (593) |
Exercise | 826 | 455 (70) | 674 (2167) |
*Some attendees attended the group education sessions more than once.
Conclusions
The need for PC supportive care is well recognized but may be challenging to offer when the services are fragmented and time-consuming for clinicians or staff to arrange. All modules offered by the PCSC Program can be accessed with one registration. It is convenient for patients because it is housed in one location, which also facilitates communication across disciplines. We attribute the success of our program to this model and our team approach to the individual patient’s needs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Prostate Cancer Supportive Care Program.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2204P - Clinical predictors and inflammatory markers for malignant pleural mesothelioma prognosis: A retrospective study in a Spanish Medical Oncology Unit
Presenter: Mora Guardamagna
Session: Poster session 07
2205P - Tumor-infiltrating lymphocytes score possesses a relation with adjuvant chemo-immunotherapy benefit and cellular morphology in large-cell neuroendocrine carcinoma
Presenter: Zhiwen Luo
Session: Poster session 07
2207P - Mainstream germline genetic testing in routine oncological care of EGFR mutant non-small cell lung cancer in the United Kingdom
Presenter: Hazel O'Sullivan
Session: Poster session 07
2208P - The single-cell proteomic landscape of pulmonary lymphoepithelioma-like carcinoma
Presenter: Chi Cho
Session: Poster session 07
2209P - Mutational status of non-small cell lung cancer in Portugal: A multicentric study
Presenter: Joana Duarte
Session: Poster session 07
2210P - Reprogramming of pyrimidine metabolism drives tumorigenesis in NF2-deficient malignant pleural mesothelioma
Presenter: Duo Xu
Session: Poster session 07
2234P - Local immune-related adverse events (irAEs) are more common in tumor-bearing organs
Presenter: Steve Blum
Session: Poster session 07
2235P - Chemotherapy priming leads to hypermutability and immune surveillance in colorectal cancer
Presenter: Pietro Paolo Vitiello
Session: Poster session 07
2236P - MHC-II neoantigens and copy number alterations (CNA) drive immune checkpoint inhibitor (ICI) response in metastatic melanoma (MM)
Presenter: Benjamin Shum
Session: Poster session 07